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Abstract
Purpose—New agents are needed for patients with metastatic uterine leiomyosarcoma who
progress after treatment with doxorubicin or gemcitabine-docetaxel. Agents targeting tumor
vasculature have potential for activity in leiomyosarcoma. We aimed to assess the activity of sunitinib
in patients with recurrent uterine leiomyosarcoma who had received one or two prior therapies by
determining the frequency of patients who survived progression-free for at least six months or who
achieved objective tumor response. We also aimed to characterize the toxicity of sunitinib and to
estimate time-to-progression.
Patients and Methods—Eligible patients with uterine leiomyosarcoma were treated with
sunitinib 50 mg by mouth daily for four weeks, with two weeks rest. Tumor response and progression-
free status were assessed every six weeks.
Results—Twenty-three of 25 patients enrolled were evaluable for efficacy (two wrong histologies).
The median number of cycles was one. Two of 23 patients achieved a partial response (8.7%, 90%
two-sided, binomial confidence interval (CI) 1.6 –24.9%). Four patients remained progression-free
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at six months (17.4%, 90% two-sided, binomial confidence interval 6.2–35.5%). Toxicities included:
grade 3 neutropenia (17.4%); grade 3 thrombocytopenia (13%); grade 3 anemia (17.4%); grade 3–4
lymphopenia (8.7%); grade 3–4 fatigue (30%); grade 3 vomiting/diarrhea (21.7%); skin rash/hand-
foot syndrome, grade 2 (13%), grade 3 (4.3%); hypertension, grade 2 (39%), grade 3 (4.3%); grade
2 decrease in cardiac ejection fraction (4.3%), and grade 3 thrombosis (4.3%). Median progression-
free survival was 1.5 months.
Conclusion—Sunitinib fails to achieve sufficient objective response or sustained disease




Uterine leiomyosarcoma (LMS) is a high-risk malignancy that is diagnosed in only a few
thousand women each year in the United States.1 Median survival for women with advanced
or unresectable, recurrent disease is less than one year.2 Treatment regimens that can achieve
objective response in patients with advanced or recurrent uterine LMS include doxorubicin
with or without ifosfamide (response rates 25–30%) and fixed dose-rate gemcitabine plus
docetaxel (response rate 35.8% as first-line treatment; 27% as second-line treatment).3–6
Single agents with moderate activity in LMS include ifosfamide (response rate 17.2%) and
gemcitabine (bolus infusion achieved a 20% response rate among women with uterine LMS
who had received 0–1 prior cytotoxic regimen).7,8 In soft tissue sarcoma, trabectedin achieved
a response rate of 8% among patients with prior treatment and 17% as first-line therapy.9,10
Trabectedin is currently being studied as first-line treatment for advanced uterine LMS in a
Gynecologic Oncology Group (GOG) phase II study. Phase II trials have shown the following
agents to be inactive: cisplatin, mitoxantrone, amonifide, oral etoposide, diazoquone (AZQ),
intravenous etoposide, topotecan, paclitaxel, thalidomide, and trimetrexate.11–21
Novel agents are needed for uterine LMS as no treatment regimen is curative. Interruption of
the vascular endothelial growth factor (VEGF) pathway is a novel approach to cancer therapy
that may reduce tumor vascularity and thus limit tumor growth. VEGF and/or VEGF receptors
are expressed in a variety of tumor types, including gynecologic cancers, with higher levels of
vascularity associated with poorer prognosis.22–25 VEGF-trap (aflibercept) has been shown to
inhibit tumor growth in mouse xenograft models, including a rhabdomyosarcoma model.26 In
a phase I study of single-agent, intravenous aflibercept, one heavily-pretreated patient with
metastatic uterine LMS achieved a minor response.27
Sunitinib is a novel, multi-targeted, small molecule in hibitor of the receptor tyrosine kinases
(RTKs) involved in tumor proliferation and angiogenesis, including vascular endothelial
growth factor receptor-1 (VEGFR-1), -2, and -3, platelet-derived growth factor receptor
(PDGFR) -α and -β, stem cell factor receptor (KIT), the tyrosine kinase (TK) receptor encoded
by the ret proto-oncogene, and fms-like tyrosine kinase 3 (Flt3).28 Chronic oral dosing with
sunitinib is expected to inhibit PDGF- and VEGF-driven angiogenesis and as a consequence,
limit solid tumor growth. Because angiogenesis is necessary for the growth and metastasis of
solid tumors, and VEGF is believed to have a pivotal role in this process, sunitinib treatment
may have clinical activity in uterine LMS.
The Gynecologic Oncology Group (GOG) conducted this phase II trial of sunitinib to determine
the activity of sunitinib as second-line or third-line therapy among women with advanced or
recurrent uterine LMS. Because a tumor vasculature-targeted agent was expected to preserve
disease stability more than achieve objective response, the trial was designed to consider
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Women with persistent or recurrent uterine leiomyosarcoma after treatment with one or two
prior cytotoxic regimens, and who had measurable disease that was not considered curable
were eligible for this study. Histologic confirmation was required and accomplished by central
review of the GOG Pathology Committee. Prior hormonal therapy was permitted, but prior
anti-angiogenic/non-cytotoxic treatment was not. Patients were permitted to have had prior
pelvic radiotherapy for uterine LMS. Prior surgery, chemotherapy and/or radiation must have
been completed at least four weeks prior to enrollment.
Patients were required to have GOG performance status of 0–2, and adequate bone marrow
function (absolute neutrophil count (ANC) greater than or equal to 1,500/microliter, platelets
greater than or equal to 100,000/microliter, hemoglobin greater than or equal to 9 gm/dl); renal
function (creatinine less than or equal to 1.5 ×institutional upper limit of normal); hepatic
function (bilirubin less than or equal to 1.5 ×institutional upper limit of normal, and serum
glutamic oxaloacetic transaminase (SGOT) and alkaline phosphatase less than or equal to 2.5
× institutional upper limit of normal); and neurologic function (baseline neuropathy (sensory
and motor) less than or equal to Common Toxicity Criteria grade 1).
Patients were required to have adequate cardiac function (baseline electrocardiogram with QTc
< 500 milliseconds and without evidence of serious ventricular arrhythmia, and measured
cardiac ejection fraction within the institutional range of normal) and adequate blood pressure
control (systolic blood pressure less than 140 mmHg, and diastolic blood pressure less than 90
mmHg). Patients requiring therapeutic doses of warfarin were not eligible; however treatment
with therapeutic doses of low molecular weight heparin was permitted, provided the
international normalized ratio was less than or equal to 1.5. Patients unable to swallow and
absorb tablets were not eligible. Patients with a serious or non-healing wound, ulcer, bone
fracture, history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
within 28 days of treatment, any history of cerebrovascular accident (CVA) or transient
ischemic attack within 12 months prior to study entry, history of myocardial infarction, cardiac
arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/
peripheral artery bypass graft or stenting within 12 months prior to study entry, history of
pulmonary embolism within the past 12 months, or Class III or IV heart failure as defined by
the New York Heart Association (NYHA) functional classification system were not eligible.
Concomitant use of the potent inducers or inhibitors of CYP3A4 (for example: amiodarone,
isoniazid, aminoglutethimide) was not permitted.
All patients signed written, informed consent. The protocol and consent were reviewed and
approved annually by participating institutions’ Institutional Review Boards.
Treatment plan
All participants had baseline imaging (magnetic resonance imaging (MRI), or computed
tomography (CT) scan of chest, abdomen, and pelvis) within four weeks of starting therapy,
which was repeated following every six-week cycle of treatment to assess response. History
and physical examination, and assessment of toxicities were done each cycle. Complete blood
counts were monitored weekly and comprehensive metabolic panels on day one of each cycle.
Patients with NYHA class II cardiac dysfunction, a history of previous anthracycline treatment,
or a history of thoracic radiation had repeat evaluations of left ventricular ejection fraction
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every other cycle. Toxicities were graded according to National Cancer Institution Common
Toxicity Criteria version 3.0 (CTC 3.0).
Sunitinib, 50 mg by mouth, was given daily in the morning with or without food for four weeks,
followed by a two-week no-treatment rest. Six weeks was termed one cycle of treatment.
Patients completed a medication and blood pressure monitoring diary.
Treatment continued until time of objective pr ogression of disease, or unacceptable toxicity.
Patients received day one treatment of each cycle provided the ANC was greater than or equal
to 1500/microliter and platelet count greater than or equal to 100,000/microliter.
Sunitinib was held for grade 3 or 4 neutropenia or thrombocytopenia until recovery to grade 2
or less. Grade 4 neutropenia or thrombocytopenia required a dose reduction to 37.5 mg daily.
Sunitinib was also held for: grade 2 or worse neuropathy or renal toxicity; grade 3 or worse
hepatic toxicity, or fever/chills/influenza-like symptoms, or fatigue/asthenia, or hand-foot
syndrome skin toxicity. Sunitinib was held for QTc prolongation to greater than or equal to
550 milliseconds. Re-treatment with a reduced dose of sunitinib was generally permitted if
toxicity improved. Patients who developed systolic blood pressure ≥140 mmHg or diastolic
blood pressure ≥90 mmHg were treated with antihypertensive medications and monitored. If
grade 3 or 4 hypertension developed, sunitinib was held. Patients with grade 4 hypertension
were removed from study treatment. Others could be re-treated with a reduced dose once blood
pressure control was achieved. Patients with a decrease in the left ventricular ejection fraction
to below institutional normal limits had a repeat assessment after one to two weeks. If the
decreased ejection fraction was confirmed, sunitinib was discontinued. If the ejection fraction
recovered within three weeks, re-treatment with sunitinib was permitted at a reduced dose and
with careful monitoring of the ejection fraction.
Objective response and disease progression were assessed by definitions in Response
Evaluation Criteria In Solid Tumors (RECIST). Complete response (CR) is disappearance of
all target and non-target lesions and no evidence of new lesions documented by two disease
assessments at least four weeks apart. Partial response (PR) is at least a 30% decrease in the
sum of longest dimensions (LD) of all measurable target lesions taking as reference the baseline
sum of LD. There can be no unequivocal progression of non-target lesions and no new lesions.
Documentation by two disease assessments at least four weeks apart is required. In the case
where the ONLY target lesion is a solitary pelvic mass measured by physical exam, which is
not radiographically measurable, a 50% decrease in the LD is required. Progression of disease
requires at least a 20% increase in the sum of LD of target lesions taking as references the
smallest sum LD or the appearance of new lesions or death due to disease or global deterioration
due to disease. Stable disease (SD) is any condition not meeting the above criteria.
Statistical design
The primary objective of this study was to assess the efficacy and toxicity of sunitinib in patients
with recurrent or persistent LMS of the uterus. The primary endpoints of the study were the
frequency of patients who survived progression-free for at least six months and the frequency
of patients who had an objective tumor response (partial or complete). Given the importance
of drug induced toxicities, the frequency and severity of adverse events as assessed by Common
Toxicity Criteria Adverse Event v3.0 was also considered a primary endpoint. The secondary
endpoints were the duration of progression-free survival (PFS) and overall survival (OS). Time
at risk was measured from the date of registration. The endpoint for PFS was disease
progression or death. The endpoint for OS was death by any cause.
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The study employed a two-stage group sequential design with an early stopping rule in the
event that the treatment demonstrated insufficient activity.29 The targeted accrual for the first
stage was 19 eligible and evaluable patients but was allowed to deviate for administrative
purposes. If at least three patients had responses or at least five patients were observed to survive
progression-free for six months, a second stage of accrual was to be initiated with a cumulative
targeted sample size of 42 patients. If more than seven patients had responses or more than 10
patients were observed to survive progression-free for six months, then the study regimen
would be deemed clinically interesting and worthy of further investigation in a phase III trial.
The specific set of critical values depended on the actual accrual to each stage.
A historical dataset from prior GOG phase II studies in uterine leiomyosarcoma was used to
establish the proportion of patients with objective responses or with progression-free survival
of 6 months or more that were considered not clinically interesting.8, 14, 18, 20, 21 Based on an
analysis of these cohorts, it was determined that agents capable of truly achieving no more than
10% objective responses and no more than 15% progression-free survival at six months were
to be classified as not clinically interesting. In contrast, regimens capable of yielding a true
proportion of 30% of patients with objective responses or 35% PFS at six months would be
considered clinically interesting and should be considered for further assessment in a phase III
study.
If the targeted accrual was attained, then the study had at least a 48% probability of terminating
early when the agent is uninteresting. If the study continued into the second stage, the
probability of the study declaring an inactive agent as being interesting was not greater then
8.4%. The power of the study at detecting a truly active regimen (by either response or PFS
for six months) was at least 89%.29
The CONSORT diagram is provided in Figure 1.
RESULTS
Patient characteristics
Twenty-five women were enrolled on study through ten participating GOG institutions. The
first stage of accrual was completed within eight months. Twenty-three women were evaluable
for efficacy and toxicity (two patients had wrong histology on central review). The median age
was 56 (range 34 – 75). All but one patient had a GOG performance status of 0–1. Eighteen
(78.3%) were white; four (17.4%) African American; one (4.3%) American Indian. Nine
patients (39.1%) had received prior pelvic radiation. Eighteen patients (78.3%) had received
one prior cytotoxic regimen, and five patients (21.7%) had received two prior cytotoxic
regimens. In over 95% of patients, the prior therapy had been doxorubicin-based and/or
gemcitabine plus a taxane (Table 1).
Response to treatment and survival
Confirmed partial response was observed in two of 23 patients (8.7%, 90% marginally two-
sided, binomial confidence interval 1.6–24.9%). There were no complete responses. Seven
patients (30.4%) had stable disease while 14 (60.9%) had disease progression or died within
two months of study entry. Only five patients received four or more cycles of therapy. The
median number of cycles per patient was 1 (range 1–14).
Four of 23 patients (17.4%, 90% two-sided, binomial confidence interval 6.2%–35.5%)
survived progression-free for at least six months from study entry. Based on the sample size
attained in the first stage of accrual, at least four patients with tumor responses or at least five
patients who survived progression-free for six months was required before the study could
open accrual to a second stage. Therefore, the study was closed. The median PFS was 1.54
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months (95% confidence interval 1.28–3.48 months). The median OS was 15.1 months (Figure
2).
Adverse events
A summary of treatment related adverse events (defined as having an attribution to the regimen
of at least possible) for the worse grade experienced by the patients by organ (or organ system)
is provided in Table 2. Myelosuppression was observed with the following frequencies: grade
3 neutropenia (17.3%), grade 3 thrombocytopenia (13%), and grade 3 anemia (17.3%), and
grade 3–4 lymphopenia (8.6%). Constitutional symptoms were common with grade 3 fatigue
in six patients (26%) and grade 4 fatigue in one (4.3%). Grade 3 weight loss was seen in one
(4.3%) patient. One patient (4.3%) had grade 2 fever. Dermatologic toxicities (skin rash, hand-
foot syndrome, nail changes), grade 2, were observed in 3 patients (13%) and were grade 3 in
one patient (4.3%). Gastrointestinal toxicities included grade 3 nausea (8.7%), grade 3 vomiting
(8.7%), grade 3 diarrhea (13%), grade 3 dehydration (8.7%), and grade 3 anorexia (4.3%).
Hypertension grade 2 (defined as blood pressure >150/100 or a symptomatic increase in
diastolic pressure of >20 mmHg from baseline) developed in 9 of 23 patients (39%) and one
patient had grade 3 hypertension (4.3%). One patient had a grade 2 decrease in left ventricular
ejection fraction. One patient had grade 3 thrombosis (4.3%) during study treatment, and died.
The GOG Data Safety and Monitoring Board determined that the cause of death was both study
treatment and disease.
DISCUSSION
Anti-angiogenic agents have shown activity in some cytotoxic agent-refractory solid tumors
such as renal cell cancer and gastrointestinal stromal tumors (GIST).30,31 Since it was
considered that an anti-angiogenic agent may achieve, at best, disease stabilization rather than
objective response, this phase II trial was designed with a dual endpoint such that either
objective response or surviving progression-free at six months would be considered a
“success.” Specifically, the study was designed to determine whether daily oral sunitinib (four
weeks on and two weeks off) could achieve a sufficient number of objective responses or
maintain enough patients progression-free for at least six months to consider the regimen for
investigation in a fully powered randomized phase III study. Sunitinib treatment failed to meet
either of these criteria and can be considered inactive as second or third-line therapy for
advanced uterine LMS.
These sunitinib results can be compared with other agents that have been tested in the second-
line metastatic LMS setting. Gemcitabine as bolus infusion, single-agent therapy for patients
with 0–1 prior cytotoxic regimens achieved response in 20% of patients.8 A fixed-dose rate
gemcitabine plus docetaxel regimen achieved objective responses in 27% of patients as second-
line therapy.6 Trabectedin achieved objective responses in 8% of soft tissue sarcoma patients
as second-line therapy.10 Among multi-kinase inhibitor anti-angiogenic agents, in a phase II
study of sorafenib for patients with soft tissue sarcoma who had had 0–1 prior therapies,
sorafenib achieved one response in 37 patients (3%) with LMS.32 Sunitinib was studied in a
phase II study for patients with non-GIST sarcomas. Among 20 patients in the histologic cohort
that was enriched for sarcoma types that had been reported to respond to tyrosine kinase
inhibitors (including 5 patients with LMS), there were no objective responses.33 A separate
phase II study of sunitinib enrolled 36 patients with non-GIST sarcoma (12 with LMS) with
one objective response seen.34
The side effect profile for sunitinib in the uterine LMS population is of interest.
Myelosuppression, hypertension, and fatigue are common. Although gastrointestinal toxicities
consisting of nausea, vomiting and diarrhea were fairly common, there were no intestinal
perforations. However, given the small number of patients treated and the short duration of
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treatment exposure due to disease progression, it is unlikely that we would detect this relatively
rare but serious toxicity in this trial.
The PFS rate at three months and six months has been proposed as an end-point for phase II
trials in soft tissue sarcoma. It is suggested that first-line treatments should achieve progression-
free rates of ≥30–56% at six months, and second-line agents should achieve three-month
progression-free rates of ≥40%.35 By these criteria, sunitinib would be considered inactive
with fewer than 40% of patients progression-free at three months, and only 17.4% of patients
progression-free at six months. In contrast, 52% of uterine LMS patients treated with fixed
dose-rate gemcitabine plus docetaxel as second-line therapy were progression-free at six
months,6 and 18% of patients treated with single agent gemcitabine on a separate phase II trial
were progression-free at six months8 . The Gynecologic Oncology Group has tested a number
of other agents in phase II trials for patients with uterine leiomyosarcoma who had received
one prior treatment regimen. The percent of patients surviving progression-free at six months
was fewer than 15% for the following agents: paclitaxel18, trimetrexate21, thalidomide20 .
Sunitinib fails to achieve objective response or sustained disease stabilization as second or
third-line therapy among patients with advanced uterine leiomyosarcoma.
Supplementary Material
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Acknowledgments
The authors wish to thank Sandra Dascomb for her support with data acquisition and reconciliation as well as Kim
Blaser for her help with publication and Debra Heller for histologic review.
This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative
Office (CA 27469), and the Gynecologic Oncology Group Statistical and Data Center (CA 37517). The following
Gynecologic Oncology Group member institutions participated in this study: University of North Carolina at Chapel
Hill School of Medicine, Memorial Sloan-Kettering Cancer Center, The University of Texas MD Anderson Cancer
Center, Fox Chase Cancer Center, University of Oklahoma, Case Western Reserve University, University of
Wisconsin, Women and Infants-Brown University, Central Connecticut Hospital, and Community Clinical Oncology
Program.
REFERENCES
1. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma: A
Gynecologic Oncology Group Study. Cancer 1993;71:1702–1709. [PubMed: 8381710]
2. Levenback C, Rubin SC, McCormack PM, et al. Resection of pulmonary metastases from uterine
sarcomas. Gynecol Oncol 1992;45:202–205. [PubMed: 1592288]
3. Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced
leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1996;62:226–
229. [PubMed: 8751554]
4. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and Docetaxel in Patients with Unresectable
Leiomyosarcoma: Results of a Phase II Trial. J Clin Oncol 2002;20:2824–2831. [PubMed: 12065559]
5. Hensley ML, Blessing JA, Mannel R, et al. Fixed-dose rate gemcitabine plus docetaxel as first-line
therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol
Oncol 2008;109:329–334. [PubMed: 18534250]
6. Hensley ML, Blessing JA, DeGeest K, et al. Fixed-dose rate gemcitabine plus docetaxel as second-
line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Gynecol Oncol 2008;109:323–328. [PubMed: 18394689]
7. Sutton GP, Blessing JA, Barrett FJ, et al. Phase II trial of ifosfamide and mesna in leiomyosarcoma of
the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992;166:556–559. [PubMed:
1536229]
Hensley et al. Page 7













8. Look KY, Sandler A, Blessing JA, et al. Phase II trial of gemcitabine as second-line chemotherapy of
uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol 2004;92:644–
647. [PubMed: 14766260]
9. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin- 743 (ET-743) for chemotherapy-naive
patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin
Oncol 2004;23:5484–5492. [PubMed: 16110008]
10. Delaloge S, Yovine A, Taamma A, et al. Ecteinasidin-743: a marine-derived compound in advanced,
pre-treated sarcoma patients—preliminary evidence of activity. J Clin Oncol 2001;19:1248–1255.
[PubMed: 11230465]
11. Thigpen JT, Blessing JA, Beecham J, et al. Phase II trial of cisplatin as first-line chemotherapy in
patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin
Oncol 1991;9:1962–1966. [PubMed: 1941054]
12. Muss HB, Bundy BN, Adcock L, et al. Mitoxantrone in the treatment of advanced uterine sarcoma:
A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1990;13:32–34. [PubMed:
2154921]
13. Asbury R, Blessing JA, Buller R, et al. Amonafide in patients with leiomyosarcoma of the uterus: a
phase II Gynecologic Oncology Group study. Am J Clin Oncol 1998;21:145–146. [PubMed:
9537200]
14. Rose PG, Blessing JA, Soper JT, et al. Prolonged oral etoposide in recurrent or advanced
leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1998;70:267–
271. [PubMed: 9740703]
15. Slayton RE, Blessing JA, Look K, et al. A Phase II clinical trial of diazoquone (AZQ) in the treatment
of patients with recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Invest
New Drugs 1991;9:207–208. [PubMed: 1874603]
16. Slayton R, Blessing J, Angel C, et al. Phase II trial of etoposide in the management of advanced or
recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Cancer Treat Rep
1987;71:1303–1304. [PubMed: 3690545]
17. Miller DS, Blessing JA, Kilgore LC, et al. Phase II trial of topotecan in patients with advanced,
persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. Am J Clin
Oncol 2000;23:355–357. [PubMed: 10955863]
18. Gallup DG, Blessing JA, Anderson W, et al. Evaluation of paclitaxel in previously treated
leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2003;89:48–
51. [PubMed: 12694653]
19. Sutton G, Blessing JA, Ball H. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a
Gynecologic Oncology Group study. Gynecol Oncol 1999;74:346–349. [PubMed: 10479491]
20. McMeekin DS, Sill M, Benbrook D, et al. A Phase II trial of thalidomide in patients with refractory
endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group
Study. Gynecol Oncol 2007;105:508–516. [PubMed: 17306350]
21. Smith HO, Blessing JA, Vaccarello L. Trimetrexate in the treatment of recurrent or advanced
leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol
2002;84:140–144. [PubMed: 11748990]
22. Olson T, Mohanraj D, Carson LF, et al. Vascular permeability factor gene expression in normal and
neoplastic human ovaries. Cancer Res 1994;54:276–280. [PubMed: 8261452]
23. Guidi AJ, Abu-Jawdeh G, Berse G, et al. Vascular permeability factor (vascular endothelial growth
factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995;87:1237–1245.
[PubMed: 7563170]
24. Guidi AJ, Abu-Jawdeh G, Tognazzxi K, et al. Expression of vascular permeability factor (vascular
endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 1996;78:454–460.
[PubMed: 8697391]
25. Chen CA, Cheng WF, Lee CN, et al. Serum vascular endothelial growth factor in epithelial ovarian
neoplasms: correlation with patient survival. Gynecol Oncol 1999;74:235–240. [PubMed: 10419737]
26. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects.
Proc Natl Acad Sci USA 2002;99:11393–11398. [PubMed: 12177445]
Hensley et al. Page 8













27. Dupont J, Rothenberg ML, Spriggs DR, et al. Safety and pharmacokinetics of intravenous VEGF-
Trap in a phase I clinical trial of patients with advanced solid tumors. Proc Amer Soc Clin Oncol
2005;23abstract 3029
28. Investigator’s Brochure SU011248 (December 2005). New York: Pfizer, Inc. and Affiliates, New
York;
29. Sill, MW.; Yothers, G. Technical Report 2006–08. Department of Biostatistics, University at Buffalo;
A method for utilizing bivariate efficacy outcome measures to screen agents for activity in 2-stage
phase II clinical trials.
30. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of
vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients
with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16–24. [PubMed: 16330672]
31. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with
advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Lancet 2006;368:1329–1338. [PubMed: 17046465]
32. Maki RG, D'Adamo DR, Keohan ML, et al. A phase II study of sorafenib in patients with metastatic/
recurrent sarcomas. J Clin Oncol. 2009In press
33. Keohan ML, Morgan JA, D'Adamo DR, et al. Continuous daily dosing (CDD) of sunitinib (SU) in
patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial. J Clin
Oncol 2008;26(May 20 suppl; abstr 10533)
34. Vigil CE, Chiappori AA, Williams CA, et al. Phase II study of sunitinib malate (SM) in subjects with
metastatic and/or surgically unresectable non-GIST soft tissue sarcomas. J Clin Oncol 2008;26(May
20 suppl; abstr 10535)
35. Van Glabbeke M, Verweij J, Judson I, et al. Progression-free rate as the principal end-point for phase
II trials in soft tissue sarcoma. Eur J Cancer 2002;38:543–549. [PubMed: 11872347]
Hensley et al. Page 9














CONSORT diagram of patient enrollment on phase II trial of sunitinib for the treatment of
recurrent or persistent uterine leiomyosarcoma.
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Progression-free survival and overall survival among patients with advanced uterine
leiomyosarcoma treated with sunitinib (n=23). Median PFS is 1.54 months; (95% confidence
interval 1.28, 3.48). Median overall survival is 15.1 months.
PFS: progression-free survival
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 African American 4 17.4









 One regimen 18 78.3
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